Table 2.
Comparison of the geometric mean titer (GMT) and GMT ratio of the anti-RBD antibodies by age, sex, and BMI.
| N | GMT (95 % CI) |
GMT ratio |
|||||||
|---|---|---|---|---|---|---|---|---|---|
| S0 | S1 | S2 | S3 | S1/S0 | S2/S1 | S2/S0 | S3/S2 | ||
| Architect (Abbott) | |||||||||
| Overall | 385 | 7.5 (7.2–7.9) | 693 (631–760) | 7007 (6500–7555) | 1030 (963–1102) | 92 | 10 | 930 | 0.15 |
| Age | |||||||||
| 20–29 | 63 | 7.2 (6.8–7.7) | 782 (650–941) | 7772 (6421–9406) | 1481(1266–1734) | 108 | 9.9 | 1076 | 0.19 |
| 30–39 | 88 | 7.0 (6.7–7.3) | 853 (727–1001) | 8424 (7134–9947) | 1128 (988–1287) | 122 | 9.9 | 1207 | 0.13 |
| 40–49 | 132 | 7.9 (7.2–8.8) | 711 (603–839) | 6920 (6181–7748) | 979 (875–1095) | 90 | 9.7 | 873 | 0.14 |
| 50–59 | 88 | 7.9 (7.1–8.7) | 549 (439–685) | 5908 (4993–6991) | 854 (742–982) | 70 | 11 | 751 | 0.14 |
| 60–64 | 14 | 6.9 (6.7–7.1) | 364 (203–653) | 4544 (2972–6948) | 596 (393–906) | 53 | 12 | 659 | 0.13 |
| P = 0.99 | P < 0.01 | P < 0.01 | P < 0.01 | P < 0.01 | P = 0.46 | P < 0.01 | P = 0.03 | ||
| Sex | |||||||||
| Male | 126 | 7.4 (7.0–7.8) | 691 (596–800) | 6573 (5671–7620) | 1030 (910–1167) | 93 | 9.5 | 887 | 0.16 |
| Female | 259 | 7.6 (7.2–8.1) | 694 (616–781) | 7229 (6632–7879) | 1030 (950–1116) | 91 | 10 | 952 | 0.14 |
| P = 0.68 | P = 0.48 | P = 0.34 | P = 0.97 | P = 0.51 | P = 0.22 | P = 0.39 | P = 0.25 | ||
| BMI（kg/m2） | |||||||||
| <18.5 | 40 | 7.9 (6.7–9.3) | 602 (414–875) | 7710 (5746–10346) | 1236 (967–1580) | 76 | 13 | 977 | 0.16 |
| 18.5–24.9 | 279 | 7.3 (7.0–7.5) | 697 (630–771) | 6914 (6347–7533) | 1017 (945–1095) | 96 | 9.9 | 951 | 0.15 |
| ≥25 | 66 | 8.5 (7.0–10) | 735 (569–950) | 6997 (5825–8405) | 971 (797–1182) | 87 | 9.5 | 823 | 0.14 |
| P = 0.95 | P = 0.70 | P = 0.20 | P = 0.01 | P = 0.75 | P = 0.053 | P = 0.18 | P = 0.25 | ||
| Elecsys (Roche) | |||||||||
| Overall | 385 | 0.40 (0.40–0.41) | 24 (21–28) | 928 (857–1006) | 659 (614–708) | 59 | 39 | 2298 | 0.71 |
| Age (years) | |||||||||
| 20–29 | 63 | 0.40 (0.40–0.41) | 32 (23–43) | 1199 (1004–1431) | 1047 (908–1209) | 78 | 38 | 2967 | 0.87 |
| 30–39 | 88 | 0.40 (0.40–0.40) | 30 (23–39) | 1111 (939–1315) | 767 (674–873) | 75 | 37 | 2779 | 0.69 |
| 40–49 | 132 | 0.41 (0.39–0.43) | 23 (17–29) | 871 (763–995) | 607 (538–686) | 55 | 39 | 2128 | 0.70 |
| 50–59 | 88 | 0.40 (0.40–0.40) | 20 (14–28) | 756 (633–903) | 497 (430–575) | 50 | 38 | 1889 | 0.66 |
| 60–64 | 14 | 0.40 (0.40–0.40) | 9.2 (4.1–21) | 626 (395–992) | 399 (251–635) | 23 | 68 | 1564 | 0.64 |
| P = 0.37 | P < 0.01 | P < 0.01 | P < 0.01 | P < 0.01 | P = 0.86 | P < 0.01 | P = 0.03 | ||
| Sex | |||||||||
| Male | 126 | 0.40 (0.40–0.41) | 28 (22–36) | 941 (811–1093) | 627 (543–724) | 69 | 34 | 2341 | 0.67 |
| Female | 259 | 0.40 (0.40–0.41) | 22 (19–27) | 922 (838–1014) | 675 (623–731) | 55 | 41 | 2277 | 0.73 |
| P = 0.60 | P = 0.28 | P = 0.70 | P = 0.41 | P = 0.25 | P = 0.15 | P = 0.69 | P = 0.27 | ||
| BMI(kg/m2) | |||||||||
| <18.5 | 40 | 0.41 (0.39–0.42) | 17 (10–28) | 920 (678–1248) | 733 (565–950) | 41 | 55 | 2263 | 0.80 |
| 18.5–24.9 | 279 | 0.40 (0.40–0.41) | 24 (21–29) | 930 (847–1021) | 651 (601–705) | 60 | 38 | 2299 | 0.70 |
| ≥25 | 66 | 0.40 (0.40–0.40) | 28 (19–40) | 927 (768–1118) | 650 (535–790) | 70 | 33 | 2317 | 0.70 |
| P = 0.13 | P = 0.16 | P = 0.56 | P = 0.13 | P = 0.14 | P = 0.04 | P = 0.63 | P = 0.40 | ||
BMI: Body mass index; CI: confidence interval; anti-RBD: anti-SARS-CoV-2 receptor binding domain spike protein IgG.
S0: Within 1 week before the first vaccination, S1: within 1 week before the second vaccination, S2: 4–5 weeks after the second vaccination, S3: 6 months after the second vaccination.
Architect: Architect SARS-CoV-2 IgG Ⅱ Quant (Abbott Laboratories), Elecsys: Elecsys anti-SARS-CoV-2 S (Roche Diagnostics).
P values were calculated using the Jonckheere-Terpstra trend test.